JP2023534987A5 - - Google Patents

Info

Publication number
JP2023534987A5
JP2023534987A5 JP2023504029A JP2023504029A JP2023534987A5 JP 2023534987 A5 JP2023534987 A5 JP 2023534987A5 JP 2023504029 A JP2023504029 A JP 2023504029A JP 2023504029 A JP2023504029 A JP 2023504029A JP 2023534987 A5 JP2023534987 A5 JP 2023534987A5
Authority
JP
Japan
Prior art keywords
sequence
polypeptide
immunogen
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023504029A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023534987A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/042836 external-priority patent/WO2022020636A2/en
Publication of JP2023534987A publication Critical patent/JP2023534987A/ja
Publication of JP2023534987A5 publication Critical patent/JP2023534987A5/ja
Pending legal-status Critical Current

Links

JP2023504029A 2020-07-24 2021-07-22 Sars-cov2スパイクタンパク質に由来する免疫原 Pending JP2023534987A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063056396P 2020-07-24 2020-07-24
US63/056,396 2020-07-24
PCT/US2021/042836 WO2022020636A2 (en) 2020-07-24 2021-07-22 Immunogens derived from sars-cov2 spike protein

Publications (2)

Publication Number Publication Date
JP2023534987A JP2023534987A (ja) 2023-08-15
JP2023534987A5 true JP2023534987A5 (enExample) 2024-07-08

Family

ID=77412334

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023504029A Pending JP2023534987A (ja) 2020-07-24 2021-07-22 Sars-cov2スパイクタンパク質に由来する免疫原

Country Status (6)

Country Link
EP (1) EP4185322A2 (enExample)
JP (1) JP2023534987A (enExample)
AU (1) AU2021311743A1 (enExample)
CA (1) CA3189336A1 (enExample)
MX (1) MX2023001055A (enExample)
WO (1) WO2022020636A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114703147A (zh) * 2022-04-18 2022-07-05 扬州大学 一种抗SARS-CoV-2广谱中和性单克隆抗体及其杂交瘤细胞株、检测试剂盒和应用
WO2024238911A1 (en) * 2023-05-17 2024-11-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant murine pneumonia virus expressing severe acute respiratory syndrome coronavirus 2 (sars-cov-2) spike protein

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
AU705616B2 (en) 1995-04-21 1999-05-27 Cell Genesys, Inc. Generation of large genomic DNA deletions
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5994619A (en) 1996-04-01 1999-11-30 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Production of chimeric bovine or porcine animals using cultured inner cell mass cells
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
KR20010034554A (ko) 1998-03-03 2001-04-25 레이몬드, 엠. 위티 치료제로서의 cd147 결합 분자
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
JP2002522063A (ja) 1998-08-17 2002-07-23 アブジェニックス インコーポレイテッド 増加した血清半減期を有する改変された分子の生成
ES2706547T3 (es) 1998-12-23 2019-03-29 Pfizer Anticuerpos monoclonales humanos para CTLA-4
US6517529B1 (en) 1999-11-24 2003-02-11 Radius International Limited Partnership Hemodialysis catheter

Similar Documents

Publication Publication Date Title
JP2009537143A5 (enExample)
JP2023526422A5 (enExample)
JP2012501959A5 (enExample)
JP2015500827A5 (enExample)
JP2008525033A5 (enExample)
RU2005127429A (ru) Активная иммунизация для создания антител к растворимому а-бета
RU2009102815A (ru) Полипептиды из neisseria meningitidis
RU2007139915A (ru) Haemophilus influenzae типа в
JP2003527079A5 (enExample)
JP2019510739A5 (enExample)
JP2023528207A5 (enExample)
JP2023554379A5 (enExample)
CN1610697A (zh) 戊型肝炎病毒单克隆抗体或其结合活性片段及其用途
JP2013520487A5 (enExample)
JP2009520758A5 (enExample)
JP2015529677A5 (enExample)
WO2024229151A2 (en) Multimeric coronavirus binding molecules and uses thereof
JP2020117504A5 (enExample)
JP2012526059A (ja) 腸球菌由来のポリペプチド、及びワクチン接種のためのその使用
JP2009500037A5 (enExample)
CN101455846B (zh) 脱乙酰壳聚糖递送系统组装的结核基因疫苗及其制备和应用
JP2015513314A5 (enExample)
JP2020536925A5 (enExample)
ES2551699T3 (es) Composiciones, procedimientos y kits
JP2008539164A5 (enExample)